- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Valchlor gel for mycosis fungoides launches in U.S.
A topical gel, Valchlor (mechlorethamine, Actelion), is now available in the United States for patients with stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma.
A topical gel, Valchlor (mechlorethamine, Actelion), is now available in the United States for patients with stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
The topical gel treated is an alkylating drug for MF-CTCL patients who have previously used skin-directed therapy, according to a news release. It is applied once daily. The company states the drug is the first formulation of topical mechlorethamine that is approved by the Food and Drug Administration based on clinical evidence to support its use.
Valchlor, an orphan drug, was acquired by Actelion as the company merged with Ceptaris Therapeutics. The drug is distributed in the United States by Accredo Specialty Pharmacy.
Actelion also launched Valchlor Support, an assistance program for eligible patients starting therapy.
